Evidence map›Paper›PMID 37444550›Full record

ArticleCancers2023

Co-Expression of Immunohistochemical Markers MRP2, CXCR4, and PD-L1 in Gallbladder Tumors Is Associated with Prolonged Patient Survival.

Andrés Tittarelli, Omar Barría, Evy Sanders, Anna Bergqvist, Daniel Uribe Brange, Mabel Vidal, María Alejandra Gleisner, Jorge Ramón Vergara, Ignacio Niechi, Iván Flores and 4 more

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. New trends in diagnosis and management of gallbladder carcinoma.World journal of gastrointestinal oncology · 2024
    Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 2 countries.

Andrés TittarelliPrograma Institucional de Fomento a la Investigación, Desarrollo e Innovación, Universidad Tecnológica Metropolitana, Santiago 8940577, Chile.ORCID 0000-0003-4129-9734
Omar BarríaMillennium Institute on Immunology and Immunotherapy, Santiago 8380453, Chile.
Evy SandersMillennium Institute on Immunology and Immunotherapy, Santiago 8380453, Chile.
Anna BergqvistMillennium Institute on Immunology and Immunotherapy, Santiago 8380453, Chile.
Daniel Uribe BrangeLaboratorio de Biología Tumoral, Instituto de Bioquímica y Microbiología, Universidad Austral de Chile, Valdivia 5090000, Chile.
Mabel VidalMolecular and Traslational Immunology Laboratory, Department of Clinical Biochemistry and Immunology, Pharmacy Faculty, Universidad de Concepción, Concepción 4070386, Chile.
María Alejandra GleisnerMillennium Institute on Immunology and Immunotherapy, Santiago 8380453, Chile.
Jorge Ramón VergaraDepartamento de Informática y Computación, Universidad Tecnológica Metropolitana, Santiago 7800002, Chile.ORCID 0000-0001-6699-4181
Ignacio NiechiLaboratorio de Biología Tumoral, Instituto de Bioquímica y Microbiología, Universidad Austral de Chile, Valdivia 5090000, Chile.ORCID 0000-0003-1857-8698
Iván FloresMillennium Institute on Immunology and Immunotherapy, Santiago 8380453, Chile.
Cristián PeredaMillennium Institute on Immunology and Immunotherapy, Santiago 8380453, Chile.
Cristian CarrascoSubdepartamento de Anatomía Patológica, Hospital Base de Valdivia, Valdivia 5090000, Chile.
Claudia Quezada-MonrásMillennium Institute on Immunology and Immunotherapy, Santiago 8380453, Chile.
Flavio Salazar-OnfrayMillennium Institute on Immunology and Immunotherapy, Santiago 8380453, Chile.ORCID 0000-0002-1848-5697
Millennium Institute on Immunology and Immunotherapy · CLAustral University of Chile · CLMetropolitan University of Technology · CLHospital Base · CLKarolinska Institutet · SEUniversity of Concepción · CL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gallbladder cancer (GBC) is a rare pathology in Western countries. However, it constitutes a relevant health problem in Asia and Latin America, with a high mortality in middle-aged Chilean women. The limited therapeutic options for GBC require the identification of targetable proteins with prognostic value for improving clinical management support. We evaluated the expression of targetable proteins, including three epithelial tumor markers, four proteins associated with multidrug and apoptosis resistance, and eleven immunological markers in 241 primary gallbladder adenocarcinomas. We investigated correlations between tumor marker expression, the primary tumor staging, and GBC patients' survival using automated immunohistochemistry, a semi-automatic method for image analysis, univariate and multivariate statistical analyses, and machine learning algorithms. Our data show a significant association between the expression of MRP2 (

Indexed as

gallbladder cancerimmune tumor microenvironmentimmunohistochemistrymultidrug resistancetissue microarraytumor markers

Identifiers

PMID37444550
PMCPMC10340206
OpenAlexW4382982728

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.